Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNova EYE Medical Ltd

Nova EYE Medical Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.155 AUD 0.00(0%)
Last update at 2026-11-12T04:37:00Z
VOLUME
272063
Market Cap
39.89M

Momentum Score

…

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.15
Low
0.16
High
52 Week Price Range
0.10
Low
0.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Nova EYE Medical Ltd (ASX:EYE) is limited; the company appears to be a small-cap ophthalmic medical-technology and therapeutics developer. Long-term growth drivers may include demographic aging and higher prevalence of vision disorders; clinical, regulatory and commercialization progress could support value creation.

Principal risks include clinical or regulatory setbacks, funding constraints and limited liquidity, and competition from larger ophthalmology firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.15
Dividend Yield
-
Revenue TTM
34.87M
Revenue Per Share
0.12
Gross Profit TTM
25.01M
Debt / Equity
0.17
ROE
-26.07%
Net Debt
1.43M
ROCE
-27.24%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4.33M -9.06M -8.79M -17.00M -8.25M
Net income -4.33M -9.06M -8.79M -15.29M -7.50M
Selling general administrative - 1.85M 11.78M 11.26M 10.04M
Selling and marketing expenses - 17.77M 3.04M 3.20M 1.77M
Gross profit 25.01M 20.07M 20.19M 14.61M 11.34M
Reconciled depreciation - 2.26M 2.99M 2.30M 1.81M
Ebit -4.38M -11.25M -8.97M -5.74M -9.70M
Ebitda -2.21M -8.98M -5.98M -3.44M -7.89M
Depreciation and amortization 2.17M 2.26M 2.99M 2.30M 1.81M
Operating income -4.38M -11.25M -8.97M -11.78M -9.70M
Other operating expenses 39.24M 40.51M 32.29M -28.81M -16.59M
Interest expense 0.15M 0.16M 0.07M - 0.03M
Tax provision - 0.00M 0.00M -1.71M -0.75M
Interest income - 0.08M 0.12M 0.08M 0.03M
Net interest income - -0.07M 0.05M 0.05M -0.03M
Income tax expense - - -5.17M -1.71M -0.75M
Total revenue 34.87M 29.27M 23.32M 17.24M 13.63M
Total operating expenses 29.39M 31.31M 14.39M 26.39M 21.04M
Cost of revenue 9.85M 9.20M 3.13M 2.63M 2.29M
Total other income expense net 0.04M 2.19M 0.18M -5.27M 1.48M
Net income from continuing ops - -9.06M -8.79M -15.29M -7.50M
Net income applicable to common shares - -9.06M -8.79M -15.29M -7.50M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 21.59M 26.50M 29.88M 30.36M 36.62M
Intangible assets 9.20M 6.86M - 8.45M 7.17M
Other current assets 0.31M - 0.23M 1.15M 1.85M
Total liab 7.31M 7.54M 8.55M 7.17M 6.23M
Total stockholder equity 14.28M 18.97M 21.33M 23.19M 30.40M
Deferred long term liab - - - 4.87M 10.85M
Other current liab 2.43M - 1.64M 1.96M 1.46M
Common stock 59.10M - 52.71M 45.17M 37.44M
Capital stock - 58.94M - 45.17M 37.44M
Retained earnings -44.08M -39.75M -30.69M -21.90M -6.60M
Other liab - - - - 0.97M
Other assets - - - 4.94M 10.92M
Cash 0.96M 5.05M 6.15M 7.42M 8.00M
Cash and equivalents - - - 7.42M 8.00M
Total current liabilities 5.53M 5.15M 5.68M 6.27M 3.86M
Current deferred revenue - - - -0.64M -0.54M
Net debt 1.43M - -2.80M -5.89M -6.06M
Short term debt 0.61M - 0.48M 0.64M 0.54M
Short long term debt total 2.39M - 3.35M 1.53M 1.94M
Other stockholder equity - - - -23.28M -30.84M
Property plant equipment - - - 2.36M 2.94M
Total current assets 9.62M 12.33M 14.75M 14.60M 15.59M
Net tangible assets - - - 14.74M 23.22M
Net receivables 5.11M 4.11M 4.08M 2.22M 2.20M
Long term debt - - - 0.89M -
Inventory 3.24M 2.81M 4.28M 3.81M 3.54M
Accounts payable 2.49M 2.35M 3.57M 4.31M 2.41M
Accumulated other comprehensive income -0.75M - -0.69M -0.09M -0.44M
Non currrent assets other - - 11.16M 0.07M 0.07M
Non current assets total 11.96M 14.18M 15.13M 15.76M 21.04M
Capital lease obligations - 3.02M - 1.53M 1.94M
Long term debt total - - - 0.89M 1.40M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.36M -0.33M -0.70M -4.54M
Change to liabilities - - - -0.43M 0.54M
Total cashflows from investing activities -0.39M -0.36M -0.33M -0.70M -4.54M
Net borrowings - - - -0.65M -0.40M
Total cash from financing activities -0.66M 5.56M 6.91M 6.82M -0.40M
Change to operating activities - - - 0.21M 0.01M
Net income -4.33M -9.06M -8.79M -15.29M -7.50M
Change in cash -4.09M -1.10M -1.27M -0.58M -9.80M
Begin period cash flow 5.05M 6.15M 7.42M 8.00M 17.80M
End period cash flow 0.96M 5.05M 6.15M 7.42M 8.00M
Total cash from operating activities -3.12M -6.15M -7.86M -6.82M -4.72M
Issuance of capital stock - 6.17M 7.43M 7.47M -
Depreciation 2.17M - 2.99M 2.30M 1.81M
Other cashflows from investing activities - -0.07M -0.11M -0.13M -0.96M
Dividends paid - - - - 0.00M
Change to inventory -0.36M 0.29M -0.48M -0.27M -0.64M
Change to account receivables -0.98M -0.10M -1.86M -0.00M 1.82M
Sale purchase of stock - 6.17M 7.43M 7.47M 0.00M
Other cashflows from financing activities -0.66M - -0.52M -0.65M -0.40M
Change to netincome - - - 5.98M -1.42M
Capital expenditures 0.23M 0.43M 0.45M 0.80M 5.59M
Change in working capital -0.89M -0.53M -2.06M -0.27M 1.18M
Stock based compensation - - 0.04M 0.18M 0.20M
Other non cash items -0.06M -5.62M 0.00M 6.17M 0.97M
Free cash flow -3.36M -6.58M -8.31M -7.62M -10.31M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EYE
Nova EYE Medical Ltd		 -
-%		 0.15 - 70.92 1.14 2.69 1.14 -3.96
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Nova EYE Medical Ltd

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

107 Rundle Street, Kent Town, SA, Australia, 5067

61 8 8362 0193

https://www.nova-eye.com

Name Title Year Born
Mr. Victor Previn B.E., B.Eng Founder & Exec. Chairman 1958
Mr. Thomas H. Spurling AM, BSc (Hons), FRACI, FTSE, Ph.D. MD & Exec. Director 1962
Liam Cook Chief Financial Officer NA
Mr. Keith Byrne VP of Global Operations NA
Mark Flynn Investor Relations NA
Ms. Kate Hunt Head of Marketing NA
Dr. David Lubeck M.D. Chief Medical Officer NA
Mr. Bill Swaim Pres of Laserex IS Ellex (USA) NA
Mr. Joaquin V. Wolff Pres of Ellex iTrack 1958
Ms. Kimberley Menzies Group Financial Controller & Global Fin. Mang. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…